Investing

Cardiex September 2024 Quarter Update

Cardiex Limited (ASX:CDX) (the “Company”) is pleased to report its activities during the September quarter 2024.

Highlights:

Manufacturing of the initial 8,000 CONNEQT Pulse units commenced with the expected arrival of units in the USA late-November/early December.
Pulse waitlist now exceeds 20,000 with activities now focused on sales conversion.
Completed clinical validation study of wearable technology, with an FDA pre-submission meeting scheduled for November to advance the clearance process.
Completion of usability study for submission for additional OTC clearance for the Pulse.
Strong clinical sales pipeline with momentum towards new Q2 contracts.
Grand prize winner of the U.S. National Institute of Health’s RADx® Maternal Health Challenge securing US$525,000 in prize funding.
New R&D Term Loan Facility with Mitchell Asset Management to provide additional flexibility with R&D initiatives and working capital requirements.

Click here for the September Quarterly Appendix 4C

Click here for the full ASX Release

This post appeared first on investingnews.com

You May Also Like

Stock

Union members at Ford, Stellantis and General Motors have ratified a new 4½-year contract, locking in at 11% pay increases secured after a six-week...

Investing

ASX-listed Antilles Gold (ASX:AAU, OTCQB:ANTMF) is an Australian mining company focused on gold and copper projects in Cuba through joint ventures with the Cuban...

Latest News

A man accused of murdering his girlfriend in Boston before fleeing to Kenya has been re-arrested following his escape from a police station in...

Latest News

Five people have died and 49 are unaccounted for after a multi-story building collapsed Monday afternoon in the South African city of George, officials...

Disclaimer: Nationalfinancialnews.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2024 nationalfinancialnews.com